Online inquiry

IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1433MR)

This product GTTS-WQ1433MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets Aβ15-42 gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1433MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5946MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ6384MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ5208MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ2131MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ12626MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ4815MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ3735MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ15135MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SYNT-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW